Novo Nordisk
Novo Nordisk is a company. It is in Bagsvaerd, Denmark and it has a male CEO called Lars Fruergaard Jorgensen. It was founded in 1923 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Bagsvaerd
- environmental score (ESG): Try Pro to see estimate
- ESG score: Try Pro to see estimate
- CEO approval: 95 %
- CEO gender: male
- CEO: Lars Fruergaard Jorgensen
- foundation year: 1923
- industry: Biotechnology
- sector: Health Care
- revenues: 20.1B $
- employees: 49,295 people
- country: Denmark
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
Extract data
Download datasets about Novo Nordisk:
Dataset of stocks from Novo Nordisk:
Novo Nordisk is one of the companies in Denmark, companies in Biotechnology, companies in Health Care, companies in Lars Fruergaard Jorgensen, companies in Bagsvaerd and 3,456,835 companies in our database.
Talking Points
- Novo Nordisk | driving change to defeat serious chronic diseases
- Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
- Daily news about diabetes, obesity and other serious chronic diseases. We're global, but here in person for your questions and comments 💬 Community guide 👇
- Driving change to defeat diabetes and other serious chronic diseases. Join us to learn more about our latest innovations | Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and ...
- Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Apply online for jobs at Novo Nordisk